Literature DB >> 10433938

Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies.

K Murata1, M C Dalakas.   

Abstract

To examine if the muscle fibers in patients with inflammatory myopathies have the potential to behave as antigen presenting cells (APCs), we investigated the expression of costimulatory molecules BB-1, B7-1 (CD80), and B7-2 (CD86), and their counterreceptors, CD28 or CTLA-4 (CD152), in the muscle biopsies of patients with polymyositis (PM), PM associated with human immunodeficiency virus infection (HIV-PM), sporadic inclusion body myositis (s-IBM), dermatomyositis (DM), and normal or disease controls. The expression of the B7 family of molecules on the muscle fibers was limited to BB-1. In PM, HIV-PM, and s-IBM, but not the disease controls, the nonnecrotic, MHC-class I-expressing muscle fibers, invaded or not by CD8+ T cells, had prominent membrane expression of BB-1. Several of the BB-1-positive fibers bound strongly in a cell-to-cell contact with their CD28 or CTLA-4 ligands on the autoinvasive CD8+ T cells, as confirmed by confocal microscopy. By reverse transcription-polymerase chain reaction, the expression of CD28 and CTLA-4 was up-regulated in PM, HIV-PM, and s-IBM, but not the controls. Because the BB-1-positive fibers expressed MHC-class I antigen and bound to up-regulated counterreceptors CD28 and CTLA-4 on the autoinvasive CD8+ T cells only in PM, HIV-PM, and s-IBM, the BB-1 molecule in these diseases should have a functional role in antigen presentation and T cell differentiation. These findings complement recent studies and suggest that in PM, HIV-PM, and s-IBM the muscle fibers are not only targets of CD8+ cytotoxic T cells but may also behave as "professional" APC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10433938      PMCID: PMC1866856          DOI: 10.1016/s0002-9440(10)65141-3

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  24 in total

1.  Discordant expression of CD28 ligands, BB-1, and B7 on keratinocytes in vitro and psoriatic cells in vivo.

Authors:  B J Nickoloff; R S Mitra; K Lee; L A Turka; J Green; C Thompson; Y Shimizu
Journal:  Am J Pathol       Date:  1993-04       Impact factor: 4.307

2.  The genomic organization of the CD28 gene. Implications for the regulation of CD28 mRNA expression and heterogeneity.

Authors:  K P Lee; C Taylor; B Petryniak; L A Turka; C H June; C B Thompson
Journal:  J Immunol       Date:  1990-07-01       Impact factor: 5.422

3.  Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies.

Authors:  A M Emslie-Smith; K Arahata; A G Engel
Journal:  Hum Pathol       Date:  1989-03       Impact factor: 3.466

4.  Immune-mediated mechanisms and immune activation of fibroblasts in the pathogenesis of eosinophilia-myalgia syndrome induced by L-tryptophan.

Authors:  I Illa; S Dinsmore; M C Dalakas
Journal:  Hum Pathol       Date:  1993-07       Impact factor: 3.466

5.  Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation.

Authors:  V A Boussiotis; G J Freeman; J G Gribben; J Daley; G Gray; L M Nadler
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

6.  MHC class I, MHC class II and intercellular adhesion molecule-1 (ICAM-1) expression in inflammatory myopathies.

Authors:  E Bartoccioni; S Gallucci; F Scuderi; E Ricci; S Servidei; A Broccolini; P Tonali
Journal:  Clin Exp Immunol       Date:  1994-01       Impact factor: 4.330

7.  Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy.

Authors:  J L De Bleecker; A G Engel
Journal:  J Neuropathol Exp Neurol       Date:  1994-07       Impact factor: 3.685

8.  The costimulatory molecule B7 is expressed on human microglia in culture and in multiple sclerosis acute lesions.

Authors:  R De Simone; A Giampaolo; B Giometto; P Gallo; G Levi; C Peschle; F Aloisi
Journal:  J Neuropathol Exp Neurol       Date:  1995-03       Impact factor: 3.685

9.  Expression of the B7/BB1 activation antigen and its ligand CD28 in T-cell-mediated skin diseases.

Authors:  J C Simon; A Dietrich; V Mielke; C Wuttig; W Vanscheidt; P S Linsley; E Schöpf; W Sterry
Journal:  J Invest Dermatol       Date:  1994-10       Impact factor: 8.551

10.  CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help.

Authors:  F A Harding; J P Allison
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

View more
  21 in total

Review 1.  Treatment of inflammatory myopathy: emerging therapies and therapeutic targets.

Authors:  Siamak Moghadam-Kia; Rohit Aggarwal; Chester V Oddis
Journal:  Expert Rev Clin Immunol       Date:  2015-08-27       Impact factor: 4.473

2.  Intravenous immunoglobulin in patients with anti-GAD antibody-associated neurological diseases and patients with inflammatory myopathies: effects on clinicopathological features and immunoregulatory genes.

Authors:  Marinos C Dalakas
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

3.  Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers.

Authors:  Pietro Fratta; W King Engel; Janis McFerrin; Kelvin J A Davies; Sharon W Lin; Valerie Askanas
Journal:  Am J Pathol       Date:  2005-08       Impact factor: 4.307

Review 4.  Advances in the immunobiology and treatment of inflammatory myopathies.

Authors:  Marinos C Dalakas
Journal:  Curr Rheumatol Rep       Date:  2007-08       Impact factor: 4.592

5.  Cross-reactive cytotoxic T lymphocytes against human immunodeficiency virus type 1 protease and gamma interferon-inducible protein 30.

Authors:  R D Mason; M I Bowmer; C M Howley; M D Grant
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 6.  Pathogenesis of idiopathic inflammatory myopathies.

Authors:  Cecilia Grundtman; Ingrid E Lundberg
Journal:  Curr Rheumatol Rep       Date:  2006-06       Impact factor: 4.592

Review 7.  Targeted immunotherapy trials for idiopathic inflammatory myopathies.

Authors:  Joerg-Patrick Stübgen
Journal:  J Neurol       Date:  2012-06-30       Impact factor: 4.849

Review 8.  Abatacept as a successful therapy for myositis—a case-based review.

Authors:  Anne M Kerola; Markku J Kauppi
Journal:  Clin Rheumatol       Date:  2014-02-04       Impact factor: 2.980

Review 9.  Inflammation induced loss of skeletal muscle.

Authors:  Priya Londhe; Denis C Guttridge
Journal:  Bone       Date:  2015-11       Impact factor: 4.398

Review 10.  Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics.

Authors:  Siamak Moghadam-Kia; Chester V Oddis; Rohit Aggarwal
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.